Free
Pain Medicine  |   April 2000
Mechanisms of Nonimmunological Histamine and Tryptase Release from Human Cutaneous Mast Cells
Author Affiliations & Notes
  • Mette Veien, M.D.
    *
  • Fania Szlam, M.M.S.
  • Jeannine T. Holden, M.D.
  • Koji Yamaguchi, M.D.
    *
  • Donald D. Denson, Ph.D.
    §
  • Jerrold H. Levy, M.D.
  • *Research Fellow.
  • Research Associate.
  • Assistant Professor of Pathology.
  • §Associate Professor of Anesthesiology.
  • Professor of Anesthesiology.
Article Information
Pain Medicine
Pain Medicine   |   April 2000
Mechanisms of Nonimmunological Histamine and Tryptase Release from Human Cutaneous Mast Cells
Anesthesiology 4 2000, Vol.92, 1074-1081. doi:
Anesthesiology 4 2000, Vol.92, 1074-1081. doi:
ANAPHYLACTIC reactions represent complex acute inflammatory processes that are associated with significant morbidity and mortality rates. A key inflammatory cell in this clinical event is the mast cell. Mast cells can release histamine and tryptase through multiple mechanisms, including immunologic (by antigens) or nonimmunologic (by drugs or neurokinins) stimulation. Immunologic activation initiates the release of histamine and other mediators by a mechanism that takes 5 min to reach completion and needs influx of extracellular calcium. 1,2 Although nonimmunologic mast cell activation is not well-understood, vancomycin, 3 the calcium ionophore A23187, 4 morphine, 5 and atracurium 6,7 consistently cause degranulation. A common feature of immunologic and nonimmunologic stimulation is the release of intracellular histamine. However, histamine is cleared within minutes from the circulation; in contrast, tryptase stays elevated for 1–2 h or more and appears to be released from mast cells with histamine. Although the physiologic role of tryptase as a mediator is not clear, measurement of tryptase concentrations potentially can provide a better diagnostic tool to evaluate suspected hypersensitivity reactions if sampling is delayed or as a more specific marker for mast cell activation. 8 Schwartz et al.  9 described that tryptase can be used in vivo  as a diagnostic correlate of mast cell activation in systemic anaphylaxis and mastocytosis. However, there is some controversy about whether tryptase is released with histamine, especially if nonimmunologic degranulation occurs. Because tryptase is considered to be a better marker for immunologic activation, we investigated whether human cutaneous mast cells release tryptase with histamine if stimulated nonimmunologically with vancomycin, the calcium ionophore A23187, morphine, or atracurium.
Little information is available about the mechanisms of nonimmunologic mast cell degranulation. An understanding of the nonimmunologic mechanisms of mast cell activation may provide therapeutic approaches to treating or preventing angioedema. Therefore, we investigated whether the mast cell degranulation was calcium dependent. In addition to histamine and tryptase, eicosanoids, such as prostaglandins and leukotrienes that arise from the metabolism of arachidonic acid, are also released after immunologic activation of cutaneous mast cells to produce inflammatory responses. 1,5,10 Arachidonic acid production is thought to be associated with an activation of cytosolic phospholipase A2(PLA2) in mast cells. 11 Because the calcium ionophore A23187 can activate the Ca2+-dependent cytosolic PLA2, with a resultant increase in arachidonic acid, we evaluated the involvement of cytosolic PLA2. We also evaluated the possibility that arachidonic acid arises via  a phospholipase C (PLC) mechanism.
Materials and Methods
Isolation of Neonatal Mast Cells
Human foreskins were obtained after circumcision. The skin was immediately placed in Ca2+–Mg2+-free Hanks’ balanced salt solution (CMF-HBSS; Sigma Chemical, St. Louis, MO) at 4°C and used within 24 h of circumcision. 4,6,12–16 After removal of the subcutaneous fat the skin was weighed, chopped into 1- or 2-mm fragments, and washed twice with CMF-HBSS (10 ml/g) at room temperature. The tissue fragments were then incubated in CMF-HBSS with collagenase (20 mg/g), hyaluronidase (4 mg/g), and deoxyribonuclease (1,000 U/foreskin; Worthington Biochemical, Freehold, NJ) in a total volume of 5 ml/g wet weight of tissue for 3 h at 37°C, with constant stirring. After incubation the digested tissue was filtered through a 150-μm pore-sized Nytex cloth (Tetko, Elmsford, NJ) and washed three times with 3.5% bovine serum albumin made in CMF-HBSS (Sigma Chemical).
Short-term Culture
Dispersed cells were resuspended in RPMI-1640 (Roswel Park Memorial Institute) culture medium (10 ml/g skin) with 25 mM HEPES (Sigma Chemical), 2 mM glutamine, 5% fetal calf serum (GIBCO, Grand Island, NY), 1,000 U/ml penicillin G, and 1% gentamicin (vol/vol; Sigma Chemical). The suspension was inoculated into a Petri dish and incubated overnight at 37°C in humidified 95% air and 5% CO2.
After overnight culture, the cells were harvested and washed three times with PAG buffer (5 ml/g), [Pipes, 25 mM piperazine-N,N′-bis(-ethenesulfonic acid) (Sigma Chemical), 110 mM NaCl, 6 mM potassium chloride (KCL), and 0.1% dextrose, pH 7.4 at room temperature. They then were counted in a hemocytometer after staining with toluidine blue. Viability was assessed by trypan blue exclusion. If the assessed cell viability was less than 80%, the cells were discarded. A Wright-stained Cytospin preparation (Shandon Inc., Pittsburgh, PA) was used to determine the percentage of mast cells in each sample.
Histamine and Tryptase Release after Drug Challenge
One hundred-microliter aliquots of the cell suspension, containing between 2 × 104and 5 × 104mast cells/experimental tube were incubated in duplicate for 30 min at 37°C with the following drugs: 4.76 × 10−5M calcium ionophore A23187 (Sigma Chemical); 3 × 10−3M vancomycin (Vancocin HCl; Lilly, Indianapolis, IN); 10−3M atracurium (Tracurium; Burroughs Wellcome, Triangle Park, NC); and 2.63 × 10−3M morphine (Mallinckrodt, St. Louis, MO). The concentrations chosen were based on in vitro  data 3 and data applied to clinically relevant doses. 17 To determine the effects of calcium on histamine release, cells were incubated either in buffer from which Ca2+and Mg2+were omitted or in buffer containing 2.8 mM Ca2+and 1.0 mM Mg2+.
The release reaction was stopped by addition of 900 μl ice-cold CMF-HBSS and centrifugation at 1,000 g  for 5 min at 4°C. Collected supernatants were split into two aliquots and frozen at −70°C until analysis time. The total-release tubes had 900 μl of sterile ice water added instead. Total histamine–tryptase content of the skin mast cells was assessed by lysis of the cells by three cycles of freezing and thawing. The spontaneous release of histamine–tryptase was estimated from tubes to which buffer, instead of releasing agent, was added. Also, if the baseline release of histamine was greater than 15% of the total histamine release, the cells were deemed damaged during the preparation process and data were excluded. Histamine–tryptase release was calculated as percentage of total release. Net percentage of histamine–tryptase release is expressed as a percentage of total histamine–tryptase corrected for spontaneous release, according to the formula
Net %release = (T − B)/T · 100
where T is total histamine and B is spontaneous release.
Histamine concentrations were measured by the enzyme immunoassay method using commercially available kits (Immunotech, Westbrook, ME). Tryptase concentrations were measured using the UniCap 100 automated apparatus (Pharmacia and Upjohn, Kalamazoo, MI) and the UniCap 100 fluoroenzyme immunoassay.
Mechanisms for Nonimmunologic Degranulation
For elucidating the mechanisms of histamine and tryptase release, two different types of enzymatic inhibitors were studied using a stimulus-secretion paradigm, with histamine and tryptase release from the mast cells as the endpoint.
Phospholipase A2Inhibition by 3-(4-Octadecyl)-benzoylacrylic Acid.
3-(4-Octadecyl)-benzoylacrylic acid (OBAA; BIOMOL Research Laboratories Inc.; Plymouth Meeting, PA) is a potent inhibitor of PLA2. Ten milligrams OBAA was dissolved in 9.34 ml absolute ethanol and split into 500-μl aliquots that were stored at −70°C. Just before use, 40 μl ethanol solution was further diluted with 1:1 solution (vol/vol) of ethanol–PAG to a final concentration of 24 μM. For the inhibition studies, 5-μl aliquots of the ethanol–PAG solution were added to 100 μl cell suspensions (resulting in a final concentration of 1 μM of the inhibitor). Tubes were preincubated for 30 min at 37°C before addition of vancomycin or calcium ionophore A23187, and the cell suspensions were incubated for an additional 30 min. Ethanol in PAG (2.08%) and OBAA without addition of drugs were used as controls.
Phospholipase C Inhibition by (1-(6-((17β-3Methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U-73122). (1-(6-((17B-3-Methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione (U-73122; BIOMOL Research Laboratories Inc.) inhibits receptor-coupled generation of inositol 1,4,5-triphosphate and intracellular mobilization of Ca2+(IC50[concentration of the inhibitor that causes 50% of inhibition]= 1.0–2.1 μM) and exhibits little or no direct inhibition of PLA2and phospholipase D.
Five milligrams U-73122 was dissolved in 5 ml methylene chloride and split into 100-μl aliquots, which were stored at −70°C. Just before use, methylene chloride was evaporated under nitrogen and U-73122 was redissolved in 150 μl absolute ethanol. This was further diluted with 927 μl PAG buffer, resulting in a 199.8-μM U-73122 solution. For the inhibition studies, 5 μl PAG–ethanol solution was added to 100 μl cell suspension, resulting in 8.36 μM U-73122. Tubes were preincubated for 30 min at 37°C before addition of vancomycin or calcium ionophore A23187, and the suspensions were incubated for an additional 30 min. Ethanol in PAG (0.58%) and U-73122 without addition of mediators were used as controls.
Statistical Analysis
Results are presented as the mean and SD, and the number of experiments (n) is indicated. All two-group comparisons were performed using a paired or unpaired t  test, with the level of statistical significance set at P  < 0.05. Multigroup comparisons were made using one-way analysis of variance, followed by a Scheffépost hoc  test for multiple comparisons, with P  < 0.05 considered to be significant.
Results
Each foreskin yielded between 2 × 105and 17 × 106cells, with 4–8% being mast cells. In the presence of Ca2+and Mg2+in the incubating buffer, we found that vancomycin, calcium ionophore A23187, morphine, and atracurium resulted in significant histamine release (31 ± 5.1, 60 ± 14.2, 17.4 ± 10.2, and 8.8 ± 5.2%, respectively), with an average baseline release of 6.9 ± 3.6% (fig. 1). Tryptase release was 22.7 ± 6.8, 18.1 ± 10.5, 22.2 ± 13.0, and 11.6 ± 6.3, respectively, with an average baseline release of 10.8 ± 5.9% (P  < 0.005;fig. 2). Also, there was a direct correlation between the net percentage releases of histamine and tryptase by vancomycin, morphine, and atracurium (r2= 0.6;fig. 3), but no correlation between net percentage releases of histamine and tryptase for calcium ionophore A23287.
Fig. 1. Effects of vancomycin (n = 7), calcium ionophore A23187 (n = 8), morphine (n = 8), and atracurium (n = 10) on histamine release from human cutaneous mast cells in the presence of calcium and magnesium. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
Fig. 1. Effects of vancomycin (n = 7), calcium ionophore A23187 (n = 8), morphine (n = 8), and atracurium (n = 10) on histamine release from human cutaneous mast cells in the presence of calcium and magnesium. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P 
	< 0.05).
Fig. 1. Effects of vancomycin (n = 7), calcium ionophore A23187 (n = 8), morphine (n = 8), and atracurium (n = 10) on histamine release from human cutaneous mast cells in the presence of calcium and magnesium. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
×
Fig. 2. Tryptase release for the experiments illustrated in figure 1. The tryptase release is calculated as (drug released tryptase)/(total tryptase content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
Fig. 2. Tryptase release for the experiments illustrated in figure 1. The tryptase release is calculated as (drug released tryptase)/(total tryptase content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P 
	< 0.05).
Fig. 2. Tryptase release for the experiments illustrated in figure 1. The tryptase release is calculated as (drug released tryptase)/(total tryptase content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
×
Fig. 3. Correlation between the histamine and tryptase release by vancomycin, morphine, and atracurium. The correlation is based on the calculated net histamine and tryptase release: (drug release-baseline release)/total mediator content × 100%.
Fig. 3. Correlation between the histamine and tryptase release by vancomycin, morphine, and atracurium. The correlation is based on the calculated net histamine and tryptase release: (drug release-baseline release)/total mediator content × 100%.
Fig. 3. Correlation between the histamine and tryptase release by vancomycin, morphine, and atracurium. The correlation is based on the calculated net histamine and tryptase release: (drug release-baseline release)/total mediator content × 100%.
×
If calcium and magnesium were omitted from the incubation buffer, histamine release from neonatal skin mast cells was decreased by 90% for vancomycin (8.5 ± 5.9%; baseline 6.0 ± 4.0%) and virtually abolished for morphine (5.7 ± 2.5%; baseline 5.6 ± 3.5%;P  < 0.05). Conversely, calcium had no effect on release reaction of A23187 (55.8 ± 15.1%; baseline 6.5 ± 3.7%;P  < 0.0001) or atracurium (5.4 ± 2.5%; baseline 3.7 ± 2.0%;P  = 0.0004;fig. 4). Furthermore, there was a significant difference in net percentage histamine release between Ca–Mg(+) and Ca–Mg(−) groups if vancomycin (P  < 0.0001) or morphine (P  = 0.0012) was used as the mast cell activator, but no difference was seen with calcium ionophore A23187 (P  = 0.57) or atracurium (P  = 0.85;fig. 5).
Fig. 4. Histamine release, if vancomycin (n = 8), calcium ionophore A23187 (n = 11), morphine (n = 11), or atracurium (n = 9) is added to human cutaneous mast cells without calcium and magnesium in the buffer. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
Fig. 4. Histamine release, if vancomycin (n = 8), calcium ionophore A23187 (n = 11), morphine (n = 11), or atracurium (n = 9) is added to human cutaneous mast cells without calcium and magnesium in the buffer. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P 
	< 0.05).
Fig. 4. Histamine release, if vancomycin (n = 8), calcium ionophore A23187 (n = 11), morphine (n = 11), or atracurium (n = 9) is added to human cutaneous mast cells without calcium and magnesium in the buffer. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
×
Fig. 5. Comparison of the histamine release with or without calcium and magnesium in the buffer. The comparison is based on the calculated net histamine release: (drug release − baseline release)/(total histamine content) × 100%. The number above each bar graph represents the number of experiments for each drug. *Significant difference in the histamine release (P  < 0.05).
Fig. 5. Comparison of the histamine release with or without calcium and magnesium in the buffer. The comparison is based on the calculated net histamine release: (drug release − baseline release)/(total histamine content) × 100%. The number above each bar graph represents the number of experiments for each drug. *Significant difference in the histamine release (P 
	< 0.05).
Fig. 5. Comparison of the histamine release with or without calcium and magnesium in the buffer. The comparison is based on the calculated net histamine release: (drug release − baseline release)/(total histamine content) × 100%. The number above each bar graph represents the number of experiments for each drug. *Significant difference in the histamine release (P  < 0.05).
×
Preincubation of the dispersed mast cells with the secretory PLA2inhibitor OBAA attenuated vancomycin-induced histamine release from 19.4 ± 8.5% to 9.3 ± 6.3% (baseline: 6.0 ± 2.7%; control: 5.8 ± 2.3%; OBAA: 6.4 ± 2.9%); whereas the calcium ionophore A23187–induced histamine release was not affected (77.0 ± 28.7 vs.  73.3 ± 17.4%; baseline 7.3 ± 2.0%; control: 7.1 ± 1.1%; OBAA: 7.6 ± 1.6%;fig. 6).
Fig. 6. Histamine release if the mast cells are preincubated with the phospholipase A2inhibitor 3-(4-octadecyl)-benzoylacrylic acid (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P  < 0.05). Comparison performed using analysis of variance.
Fig. 6. Histamine release if the mast cells are preincubated with the phospholipase A2inhibitor 3-(4-octadecyl)-benzoylacrylic acid (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P 
	< 0.05). Comparison performed using analysis of variance.
Fig. 6. Histamine release if the mast cells are preincubated with the phospholipase A2inhibitor 3-(4-octadecyl)-benzoylacrylic acid (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P  < 0.05). Comparison performed using analysis of variance.
×
For the PLC inhibitor U-73122 we found a similar pattern as for the PLA2inhibitor: It abolished vancomycin-induced histamine release but not calcium ionophore A23187–induced histamine release. For the vancomycin group, data were as follows: baseline: 5.2 ± 3.4%; control: 5.5 ± 2.8%; U-73122: 8.9 ± 3.8%; U-73122 with vancomycin: 9.3 ± 3.8%; and vancomycin: 35.3 ± 18.7%. For the calcium ionophore A23187 group, values were as follows: baseline: 7.3 ± 3.0%; control: 5.7 ± 2.3%; U-73122: 8.2 ± 3.4%; U73122 and A23187: 80.4 ± 18.9%; and A23187: 77.3 ± 19.4%. The groups were compared using analysis of variance, and we found a significant release for vancomycin alone, for U73122 with A23187, and for A23187 (P  = 0.05), compared with the baseline and the control (fig. 7).
Fig. 7. Histamine release if the mast cells are preincubated with the phospholipase C inhibitor U-73122 (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P  < 0.05). Comparison performed using analysis of variance.
Fig. 7. Histamine release if the mast cells are preincubated with the phospholipase C inhibitor U-73122 (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P 
	< 0.05). Comparison performed using analysis of variance.
Fig. 7. Histamine release if the mast cells are preincubated with the phospholipase C inhibitor U-73122 (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P  < 0.05). Comparison performed using analysis of variance.
×
Discussion
We found that tryptase is released in addition to histamine during nonimmunologic processes by known mast cell degranulators. Also, vancomycin, a prototypical mast cell degranulator, appears to be partially dependent on calcium and releases histamine and tryptase via  PLC- and PLA2-dependent mechanisms. This may be a result of either direct action on PLC and PLA2by vancomycin or stimulation of an unknown receptor mechanism. Our finding of significant tryptase release by vancomycin differs from the result described in a recent publication by Renz et al.  18 Those authors looked at plasma levels of tryptase and histamine in patients receiving rapid vancomycin infusion and saw increases in plasma histamine levels only. The difference in the results may be caused by either direct activation of mast cells in vitro  or the fact that only in vivo  basophil activation occurred. Conversely, mast cell degranulation induced by calcium ionophore A23187, which causes Ca2+influx and releases Ca2+from intracellular sites, such as the sarcoplasmic reticulum, 19,20 was not inhibited by PLC and PLA2inhibitors or decreased in the absence of extracellular calcium. This extracellular calcium independence on the histamine release by A23187 is opposite to the response seen in the dispersed mast cells from human lungs. Church et al.  21 reported that histamine release induced by the calcium ionophore A23187 was decreased by more than 90% if calcium was omitted from the incubation medium. Because mast cells are functionally heterogeneous and possess different characteristics, 7,22 previously described pathways from animal experiments and nonconnective tissue mast cells may not be valid for human cutaneous infant mast cells, the cells used in this study.
Our mast cell degranulation results are in accordance with other studies. Levy et al.  3 showed that vancomycin induced 22.9% histamine release. Benyon et al.  23 showed that calcium ionophore A23187 released 28.6% histamine. Stellato et al.  5 showed a significant positive correlation between the percentages of histamine and tryptase release induced by morphine from human skin mast cells, and the release was calcium dependent, and, as in our study, no release was observed if calcium was removed from the incubation buffer. 13 Atracurium is a known histamine releaser, both in vivo  24 and in vitro  (net histamine release 12% with 10−3M), 6 although another study reports that atracurium causes modest histamine release. 25 We also found only a modest release of histamine and tryptase after incubation with atracurium. Tryptase has been shown to be released with histamine from human heart and synovial mast cells, if stimulated immunologically in vitro  , 26,27 and others have shown that it is released with histamine after an immunoglobulin (Ig) E–mediated event in vivo  . 28,29 Stellato et al.  5 showed a positive correlation between the percentage of histamine and tryptase release induced by buprenorphine or by anti-IgE from human lung mast cells. Watkins 30 previously defined the nonimmune mechanisms as absence of plasma tryptase but presence of increased urinary methylhistamine excretion. According to a study by Fisher and Baldo, 31 increased concentrations of mast cell tryptase are not associated invariably with immunologic reactions. In a recent study, Edston and van Hage-Hamsten 32 found elevated levels of tryptase in heroin addicts who died suddenly after injection, indicating a possible mast cell degranulation. There was no correlation between total IgE and tryptase levels, suggesting that heroin and morphine may have activated mast cells nonimmunologically. 32 Data from our own in  vitro  study shows that tryptase also can be released, along with histamine, by nonimmunologic mast cell activation.
There was marked variability in histamine release from different foreskin preparations (all prepared using the same cell-dispersion protocol), suggesting that the ability to release influences the effect of the drugs on cutaneous mast cells. Furthermore, the number of mast cells isolated per gram of skin varied markedly, which could be another factor that influences drug sensitivity or other nonimmunologic mast cell activators.
The mechanisms for nonimmunologic mast cell activation are not well-described but suggest a dose-dependent and reproducible noncytotoxic reaction. 33 Some authors describe the reaction in vitro  to be independent of extracellular calcium 1; others describe it as partially calcium-independent 23,34; and still others find it to be dependent on extracellular calcium, with maximum release if incubated with 3-mM extracellular calcium. 4,35–36,37 Our studies with neonatal, partially purified, mast cells showed that the release was partially dependent on extracellular calcium, except in the case of the calcium ionophore A23187, which can release calcium from intracellular stores. 19,20 
Studies with peritoneal rat mast cells show that PLA2inhibitors can suppress histamine release but not prostaglandin release, if challenged with IgE or nonimmunochemical stimuli, such as calcium ionophore A23187, concanavalin A, compound 48/80, and substance P. 38 Murakami et al.  39 also showed that if rat mast cells are exposed to type II PLA2, a significant release of histamine is observed. Our studies with the human cutaneous mast cell showed decreased histamine release if PLA2or PLC was inhibited (figs. 6 and 7). Elucidating pathways responsible for the histamine and tryptase release requires further studies to obtain a better understanding of in vivo  and in vitro  mast cell activation.
Laroche et al.  40 measured concentrations of plasma histamine and tryptase after exposure to radiocontrast media in 20 patients with mild to severe reactions. Increased plasma histamine levels developed in 14 patients and increased tryptase levels developed in 16. 40 Histamine and tryptase concentrations correlated with the severity of the reaction. The authors also reported the presence of IgE against the radiocontrast agents, although radiocontrast reactions traditionally have been considered to be nonimmunologic anaphylactoid reactions. Tests to determine IgE antibodies against radiocontrast agents are not validated; the authors did not perform inhibition studies to further validate their assay; and radiocontrast reactions occurred without previous exposure, suggesting that the reactions they noted were anaphylactoid.
Based on our in vitro  study, we conclude that tryptase is released with histamine during nonimmunologic mast cell activation and also can be an indicator for anaphylactoid reactions because it is only present in the cytoplasmic granules of mast cells. 41 The mechanism of nonimmunologic histamine and tryptase release relies on membrane associated enzymes, such as PLA2and PLC. Although the physiologic role of tryptase is not clear, it is a neutral protease that can both activate and inactivate multiple inflammatory mediators. Further elucidation of direct molecular effects of mast cell activation may be important in understanding mechanisms of anaphylactoid reactions and other pathologic states of mast cell activation.
The authors thank Dr. Maria E. Arias and the staff at Georgia Baptist Hospital, Atlanta, Georgia, and Dr. Raphael Gershon and the staff at Grady Memorial Hospital, Atlanta, Georgia, for collecting the foreskins.
References
Caulfield JP, El-Lati S, Thomas G, Church MK: Dissociated human foreskin mast cells degranulate in response to anti-IgE and substance P. Lab Invest 1990; 63:502–10Caulfield, JP El-Lati, S Thomas, G Church, MK
Tharp MD, Suvunrugsi RT, Sullivan TJ: IgE-mediated release of histamine from human cutaneous mast cells. J Immunol 1983; 130:1896–901Tharp, MD Suvunrugsi, RT Sullivan, TJ
Levy JH, Kettlekamp N, Goertz P, Hermens J, Hirshman CA: Histamine release by vancomycin: A mechanism for hypotension in man. A NESTHESIOLOGY 1987; 67:122–5Levy, JH Kettlekamp, N Goertz, P Hermens, J Hirshman, CA
Benyon CR, Church MK, Clegg SL, Holgate ST: Dispersion and characterisation of mast cells from human skin. Int Arch Allergy Appl Immunol 1986; 79:332–4Benyon, CR Church, MK Clegg, SL Holgate, ST
Stellato C, Cirillo R, Paulis AD, Casolaro V, Patella V, Mastronardi P, Mazzarella B, Marone G: Human basophil/mast cell releasability: IX. Heterogeneity of the effects of opioids on mediator release. A NESTHESIOLOGY 1992; 77:932–40Stellato, C Cirillo, R Paulis, AD Casolaro, V Patella, V Mastronardi, P Mazzarella, B Marone, G
North FC, Kettelkamp N, Hirshman CA: Comparison of cutaneous and in vitro histamine release by relaxants. A NESTHESIOLOGY 1987; 66:543–6North, FC Kettelkamp, N Hirshman, CA
Stellato C, Paulis AD, Cirillo R, Mastronardi P, Mazzarella P, Marone G: Heterogeneity of human mast cells and basophils in response to muscle relaxants. A NESTHESIOLOGY 1991; 74:1078–86Stellato, C Paulis, AD Cirillo, R Mastronardi, P Mazzarella, P Marone, G
Hogan AD, Schwartz LB: Markers of mast cell degranulation. Methods 1997; 13:43–52Hogan, AD Schwartz, LB
Schwartz LB, Metcalfe DD, Miller JS, Earl H, Sullivan T: Tryptase levels as an indicator of mast cell activation in systemic anaphylaxis and mastocytosis. N Engl J Med 1987; 316:1622–6Schwartz, LB Metcalfe, DD Miller, JS Earl, H Sullivan, T
Benyon CR, Robinson C, Church MK: Differential release of histamine and eicosanoids from human skin mast cells activated by IgE-dependent and non-immunological stimuli. Br J Phamacol 1989; 97:898–904Benyon, CR Robinson, C Church, MK
Murakami M, Nakatani Y, Atsumi G, Inoue K, Kudo I: Regulatory functions of phospholipase A2. Crit Rev Immunol 1997; 17:225–83Murakami, M Nakatani, Y Atsumi, G Inoue, K Kudo, I
Hirshman CA, Edelstein RA, Ebertz MJ, Hanifin JM: Thiobarbiturate-induced histamine release in human skin mast cells. A NESTHESIOLOGY 1985; 63:353–6Hirshman, CA Edelstein, RA Ebertz, MJ Hanifin, JM
Lawrence ID, Warner JA, Cohan VL, Hubbard WC, Kagey-Sobotka A, Lichtenstein LM: Purification and characterization of human skin mast cells. Evidence for human mast cell hetrogeneity. J Immunol 1987; 139:3062–9Lawrence, ID Warner, JA Cohan, VL Hubbard, WC Kagey-Sobotka, A Lichtenstein, LM
Sauder RA, Hirshman CA: Protamine-induced histamine release in human skin mast cells. A NESTHESIOLOGY 1990; 73:165–7Sauder, RA Hirshman, CA
Paulis AD, Stellato C, Cirillo R, Ciccarelli A, Oriente A, Marone G: Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992; 99:723–8Paulis, AD Stellato, C Cirillo, R Ciccarelli, A Oriente, A Marone, G
Okayama Y, El-Lati SG, Leiferman KM, Church MK: Eosinophil granule proteins inhibit substance P-induced histamine release from human skin mast cells. J Allergy Clin Immunol 1994; 93:900–9Okayama, Y El-Lati, SG Leiferman, KM Church, MK
Levy JH, Adelson A, Walker B: Wheal and flare responses to muscle relaxants in humans. Agents Actions 1991; 34:302–8Levy, JH Adelson, A Walker, B
Renz CL, Laroche D, Thurn JD, Finn HA, Lynch JP, Thisted R, Moss J: Tryptase levels are not increased during vancomycin-induced anaphylactoid reactions. A NESTHESIOLOGY 1998; 89:620–5Renz, CL Laroche, D Thurn, JD Finn, HA Lynch, JP Thisted, R Moss, J
Pressman BC: Biological applications of ionophores. Annu Rev Biochem 1976; 45:501–30Pressman, BC
Takamori M, Yoshihiko Y, Mitsuhiro T: Pharmacophysiological study on muscle treated with calcium ionophore A23187. J Neurol Sci 1981; 50:89–94Takamori, M Yoshihiko, Y Mitsuhiro, T
Church MK, Pao GJK, Holgate ST: Characterization of histamine secretion from mechanically dispersed human lung mast cells: Effects of anti-IgE, calcium ionophore A23187, compound 48/80, and basic polypeptides. J Immunol 1982; 129:2116–21Church, MK Pao, GJK Holgate, ST
Weidner N, Austen FK: Evidence for morphologic diversity of human mast cells: An ultrastructural study of mast cells from multiple body sites. Lab Invest 1990; 63:63–71Weidner, N Austen, FK
Benyon CR, Lowman MA, Church MK: Human skin mast cells: Their dispersion, purification, and secretory characterization. J Immunol 1987; 138:861–7Benyon, CR Lowman, MA Church, MK
Naguib M, Samarkandi AH, Bakhamees HS, Magboul MA, El-Bakry AK: Histamine release haemodynamic changes produced by rocuronium, vecuronium, mivacurium, atracurium and tubocurarine. Br J Anaesth 1995; 75:588–92Naguib, M Samarkandi, AH Bakhamees, HS Magboul, MA El-Bakry, AK
Doenicke A, Moss J, Lorenz W, Hoernecke R, Gottardis M: Are hypotension and rash after atracurium really caused by histamine release? Anesth Analg 1994; 78:967–72Doenicke, A Moss, J Lorenz, W Hoernecke, R Gottardis, M
Patella V, Marinò I, Lampärter B, Arbustini E, Adt M, Marone G: Human heart mast cells: Isolation, purification, ultrastructure, and immunologic characterization. J Immunol 1995; 154:2855–65Patella, V Marinò, I Lampärter, B Arbustini, E Adt, M Marone, G
Paulis AD, Marinò I, Ciccarelli A, Crescenzo GD, Concardi M, Verga L, Arbustini E, Marone G: Human synovial mast cells: Ultrastructural in situ and in vitro immunologic characterization. Arthritis Rheum 1996; 39:1222–33Paulis, AD Marinò, I Ciccarelli, A Crescenzo, GD Concardi, M Verga, L Arbustini, E Marone, G
Schwartz LB, Yunginger JW, Miller J, Bokhari R, Dull D: Time course of appearance and disappearance of human mast cell tryptase in the circulation after anaphylaxis. J Clin Invest 1989; 83:1551–5Schwartz, LB Yunginger, JW Miller, J Bokhari, R Dull, D
Laroche D, Vergnaud MC, Sillard B, Soufarapis H, Bricard H: Biochemical markers of anaphylactoid reactions to drugs. A NESTHESIOLOGY 1991; 75:945–9Laroche, D Vergnaud, MC Sillard, B Soufarapis, H Bricard, H
Watkins J: Adverse reaction to neuromuscular blockers: Frequency, investigation, and epidemiology. Acta Anaesthesiol Scand 1994; 38(suppl 102):6–10Watkins, J
Fisher MM, Baldo BA: Mast cell tryptase in anaesthetic anaphylactoid reactions. Br J Anaesth 1998; 80:26–9Fisher, MM Baldo, BA
Edston E, van Hage-Hamsten M: Anapylactic shock: A common cause of death in heroin addicts? Allergy 1997; 52:959–4Edston, E van Hage-Hamsten, M
Levy JH: Nonimmunologic (Pharmacologic) Histamine Release, Anaphylactic Reactions in Anesthesia and Intensive Care, 2nd edition. Stoneham, Butterworth-Heinemann, 1992, pp 63–80
Lowman MA, Benyon CR, Church MK: Characterization of neuropeptide-induced histamine release from human dispersed skin mast cells. Br J Pharmacol 1988; 95:121–30Lowman, MA Benyon, CR Church, MK
Erbertz JM, Hermens JM, McMillan JC, Uno H, Hirshman CA, Hanifin JM: Functional differences between human cutaneous mast cells and basophils: A comparison of morphine-induced histamine release. Agents Action 1986; 18:455–62Erbertz, JM Hermens, JM McMillan, JC Uno, H Hirshman, CA Hanifin, JM
Stellato C, Paulis AD, Cicarelli A, Cirillo R, Patella V, Casolaro V, Marone G: Anti-inflammatory effect of cyclosporin A on human skin mast cells. J Invest Dermatol 1992; 98:800–4Stellato, C Paulis, AD Cicarelli, A Cirillo, R Patella, V Casolaro, V Marone, G
El-Lati SG, Dahinden CA, Church MK: Complement peptides C3a- and C5a-induced mediator release from dissociated human skin mast cells. J Invest Dermatol 1994; 102:803–6El-Lati, SG Dahinden, CA Church, MK
Murakami M, Kudo I, Suwa Y, Inoue K: Release of 14 kDa group-II phopholipase A2from activated mast cells and its possible involvement in the regulation of the degranulation process. Eur J Biochem 1992; 209:257–65Murakami, M Kudo, I Suwa, Y Inoue, K
Murakami M, Hara N, Kudo I, Inoue K: Triggering of degranulation in mast cells by exogenous type II phospolipase A2. J Immunol 1993; 151:5675–84Murakami, M Hara, N Kudo, I Inoue, K
Laroche D, Gastin-Aimone I, Dubois F, Huet H, Gerard P, Vergnaud MC, Mouton-Faivre C, Gueant JL, Laxenaire MC, Bricard H: Mechanism of severe, immediate reactions to iodinated contrast material. Radiology 1998; 209:183–90Laroche, D Gastin-Aimone, I Dubois, F Huet, H Gerard, P Vergnaud, MC Mouton-Faivre, C Gueant, JL Laxenaire, MC Bricard, H
Schwartz LB: Mediators of human mast cells and human mast cell subsets. Ann Allergy 1987; 58:226–37Schwartz, LB
Fig. 1. Effects of vancomycin (n = 7), calcium ionophore A23187 (n = 8), morphine (n = 8), and atracurium (n = 10) on histamine release from human cutaneous mast cells in the presence of calcium and magnesium. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
Fig. 1. Effects of vancomycin (n = 7), calcium ionophore A23187 (n = 8), morphine (n = 8), and atracurium (n = 10) on histamine release from human cutaneous mast cells in the presence of calcium and magnesium. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P 
	< 0.05).
Fig. 1. Effects of vancomycin (n = 7), calcium ionophore A23187 (n = 8), morphine (n = 8), and atracurium (n = 10) on histamine release from human cutaneous mast cells in the presence of calcium and magnesium. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
×
Fig. 2. Tryptase release for the experiments illustrated in figure 1. The tryptase release is calculated as (drug released tryptase)/(total tryptase content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
Fig. 2. Tryptase release for the experiments illustrated in figure 1. The tryptase release is calculated as (drug released tryptase)/(total tryptase content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P 
	< 0.05).
Fig. 2. Tryptase release for the experiments illustrated in figure 1. The tryptase release is calculated as (drug released tryptase)/(total tryptase content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
×
Fig. 3. Correlation between the histamine and tryptase release by vancomycin, morphine, and atracurium. The correlation is based on the calculated net histamine and tryptase release: (drug release-baseline release)/total mediator content × 100%.
Fig. 3. Correlation between the histamine and tryptase release by vancomycin, morphine, and atracurium. The correlation is based on the calculated net histamine and tryptase release: (drug release-baseline release)/total mediator content × 100%.
Fig. 3. Correlation between the histamine and tryptase release by vancomycin, morphine, and atracurium. The correlation is based on the calculated net histamine and tryptase release: (drug release-baseline release)/total mediator content × 100%.
×
Fig. 4. Histamine release, if vancomycin (n = 8), calcium ionophore A23187 (n = 11), morphine (n = 11), or atracurium (n = 9) is added to human cutaneous mast cells without calcium and magnesium in the buffer. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
Fig. 4. Histamine release, if vancomycin (n = 8), calcium ionophore A23187 (n = 11), morphine (n = 11), or atracurium (n = 9) is added to human cutaneous mast cells without calcium and magnesium in the buffer. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P 
	< 0.05).
Fig. 4. Histamine release, if vancomycin (n = 8), calcium ionophore A23187 (n = 11), morphine (n = 11), or atracurium (n = 9) is added to human cutaneous mast cells without calcium and magnesium in the buffer. The histamine release is calculated as (drug released histamine)/(total histamine content) × 100%. The baseline for each group of drugs is presented together with the drug release. *Significant difference from baseline release (P  < 0.05).
×
Fig. 5. Comparison of the histamine release with or without calcium and magnesium in the buffer. The comparison is based on the calculated net histamine release: (drug release − baseline release)/(total histamine content) × 100%. The number above each bar graph represents the number of experiments for each drug. *Significant difference in the histamine release (P  < 0.05).
Fig. 5. Comparison of the histamine release with or without calcium and magnesium in the buffer. The comparison is based on the calculated net histamine release: (drug release − baseline release)/(total histamine content) × 100%. The number above each bar graph represents the number of experiments for each drug. *Significant difference in the histamine release (P 
	< 0.05).
Fig. 5. Comparison of the histamine release with or without calcium and magnesium in the buffer. The comparison is based on the calculated net histamine release: (drug release − baseline release)/(total histamine content) × 100%. The number above each bar graph represents the number of experiments for each drug. *Significant difference in the histamine release (P  < 0.05).
×
Fig. 6. Histamine release if the mast cells are preincubated with the phospholipase A2inhibitor 3-(4-octadecyl)-benzoylacrylic acid (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P  < 0.05). Comparison performed using analysis of variance.
Fig. 6. Histamine release if the mast cells are preincubated with the phospholipase A2inhibitor 3-(4-octadecyl)-benzoylacrylic acid (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P 
	< 0.05). Comparison performed using analysis of variance.
Fig. 6. Histamine release if the mast cells are preincubated with the phospholipase A2inhibitor 3-(4-octadecyl)-benzoylacrylic acid (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P  < 0.05). Comparison performed using analysis of variance.
×
Fig. 7. Histamine release if the mast cells are preincubated with the phospholipase C inhibitor U-73122 (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P  < 0.05). Comparison performed using analysis of variance.
Fig. 7. Histamine release if the mast cells are preincubated with the phospholipase C inhibitor U-73122 (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P 
	< 0.05). Comparison performed using analysis of variance.
Fig. 7. Histamine release if the mast cells are preincubated with the phospholipase C inhibitor U-73122 (n = 6). The histamine release is calculated as (drug-released histamine)/(total histamine content) × 100%. *Significant difference from baseline or control release (P  < 0.05). Comparison performed using analysis of variance.
×